Neisvac-C

Neisseria meningitidis group C polysaccharide (de-O-acetylated) conjugated to tetanus toxoid, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It is employed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup C in children, adolescents, and adults who are at risk.

GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for vaccine distribution.

Neisvac-C is a conjugate meningococcal vaccine that targets the polysaccharide capsule of Neisseria meningitidis serogroup C.

Meningococcal group C disease: provides active immunity to prevent invasive infection caused by serogroup C strains. Outbreak control: reduces transmission during community or institutional serogroup C outbreaks. Travel protection: safeguards travelers to regions where serogroup C meningococcal disease is endemic. Adolescent immunisation programmes: integrates into routine vaccination schedules for teenagers to maintain herd immunity. High‑risk patient protection: recommended for individuals with complement deficiencies or asplenia to lower disease risk.

Neisvac-C, like other conjugate vaccines, may be associated with local and systemic reactions after injection.

Common Side Effects: - Injection site pain, redness or swelling. - Mild fever within 24‑48 hours. - Headache or fatigue. - Transient muscle aches.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Guillain‑Barré syndrome. - Seizures or high‑grade fever. - Hypotension or shock. - Immune thrombocytopenia. - Persistent neurological symptoms.

Before administering Neisvac-C, healthcare professionals should consider the following precautions.

Allergy assessment: avoid use in individuals with known hypersensitivity to any vaccine component. Pregnancy: consult a healthcare provider as safety data are limited. Immunocompromised patients: vaccine may be less effective; monitor response. Fever monitoring: observe for high fever post‑vaccination and manage symptomatically. Concurrent vaccines: follow recommended intervals when co‑administering other immunisations. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccine interactions are generally limited, but certain co‑administrations require attention.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration with Neisvac-C. - Blood products: avoid within four weeks of vaccination.

Moderate Interactions (Monitor Closely): - Immunoglobulin therapy: may reduce vaccine‑induced antibody response. - Immunosuppressive drugs: may diminish protective immunity. - Antipyretics: can mask fever, a common post‑vaccination sign. - Other vaccines: adhere to recommended spacing intervals.